Copertina

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Melinda J. Gooderham, Jonathan I. Silverberg, Marjolein De Bruin‐Weller, Leon Kircik, Diamant Thaçi, Zuotao Zhao, Fernando Valenzuela, Toshifumi Nomura, Andrew Selfridge, Dorothy Fan, Daniela E. Myers, Pinaki Biswas, Saleem A. Farooqui, Melissa Watkins, Herwig Koppensteiner
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Journal of the European Academy of Dermatology and Venereology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
di: Jonathan I. Silverberg, et al.
Pubblicazione: (2026)

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
di: Diamant Thaçi, et al.
Pubblicazione: (2025)

Reply to ‘Delayed absorption and systemic variability of topical delgocitinib in Chronic Hand Eczema’
di: Diamant Thaçi, et al.
Pubblicazione: (2025)

The real‐world, long‐term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study
di: Khalaf Kridin, et al.
Pubblicazione: (2025)

Real‐world evidence for comprehensive evaluation of guselkumab in the treatment of psoriasis
di: Diamant Thaçi
Pubblicazione: (2025)

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
di: Lian F. van der Gang, et al.
Pubblicazione: (2025)

Drug survival of abrocitinib compared to dupilumab in adult patients with atopic dermatitis
di: Qingjie Hu, et al.
Pubblicazione: (2024)

Extensive cutaneous viral warts during JAK inhibitor therapy for atopic dermatitis
di: Daniel Hilewitz, et al.
Pubblicazione: (2026)

Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
di: Lian F. van der Gang, et al.
Pubblicazione: (2026)

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
di: Matthias Augustin, et al.
Pubblicazione: (2025)

Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib
di: M. Bianco, et al.
Pubblicazione: (2024)

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
di: Lian F. van der Gang, et al.
Pubblicazione: (2026)

Understanding socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
di: Ilona Tadulewicz, et al.
Pubblicazione: (2025)

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity
di: Joséphine Dupuis, et al.
Pubblicazione: (2024)

Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER‐2)
di: J. I. Silverberg, et al.
Pubblicazione: (2024)

Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning
di: Koichi Ashizaki, et al.
Pubblicazione: (2024)

Long‐term socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
di: Sigrun Alba Johannesdottir Schmidt, et al.
Pubblicazione: (2025)

Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
di: M. E. Jacobson, et al.
Pubblicazione: (2025)

Treatment of moderate‐to‐severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry
di: Stephan Traidl, et al.
Pubblicazione: (2024)

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
di: Christopher G. Bunick, et al.
Pubblicazione: (2025)

Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.
di: Luca Potestio, et al.
Pubblicazione: (2024)

The long road to atopic disease modification in infants with atopic dermatitis
di: Thomas Hultsch
Pubblicazione: (2024)

French guidelines for the management of atopic dermatitis
di: Nina Sigg, et al.
Pubblicazione: (2025)

Obesity is linked to disease severity in moderate to severe atopic dermatitis—Data from the prospective observational TREATgermany registry
di: Stephan Traidl, et al.
Pubblicazione: (2024)

Phototherapy for atopic dermatitis: Is the light still shining?
di: Adrian Tanew
Pubblicazione: (2024)

International insights into bullying in patients with atopic dermatitis: Global trends and key predictors
di: Roni Dodiuk‐Gad, et al.
Pubblicazione: (2025)

Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN
di: J. P. Thyssen, et al.
Pubblicazione: (2024)

Psychological impact on flare patterns and severity of atopic dermatitis
di: Mia‐Louise Nielsen, et al.
Pubblicazione: (2024)

An alternative interpretation of the diagnosis of atopic dermatitis in the Boy with an Orange
di: Nicolas Kluger
Pubblicazione: (2026)

Infectious risk with JAKi : What about atopic dermatitis?
di: Lea Hoisnard, et al.
Pubblicazione: (2025)

Langerhans cells: Central players in the pathophysiology of atopic dermatitis
di: Yi Pan, et al.
Pubblicazione: (2024)

Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study
di: Gianluca Avallone, et al.
Pubblicazione: (2024)

T helper and IL ‐20 cytokine signatures distinguish atopic dermatitis from contact dermatitis subtypes
di: Axel De Greef, et al.
Pubblicazione: (2025)

Addressing existing gaps in the management of young adults with atopic dermatitis
di: Magdalena Trzeciak, et al.
Pubblicazione: (2024)

Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy
di: Christian Vestergaard, et al.
Pubblicazione: (2025)

Tattoos in patients with atopic dermatitis: What the dermatologist should know?
di: Nicolas Kluger
Pubblicazione: (2025)

Leveraging artificial intelligence to pursue treatment personalization in atopic dermatitis
di: Bruno Duarte
Pubblicazione: (2024)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis
di: Tiago Torres, et al.
Pubblicazione: (2026)

Impact of prior biologic exposure on drug survival in atopic dermatitis
di: Xu Li, et al.
Pubblicazione: (2025)

Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab
di: Andrew Blauvelt, et al.
Pubblicazione: (2025)